Leukapheresis Market is projected to reach $98 million by 2027 Globally, at a CAGR of 8.5% - Exclusive Report by MarketsandMarkets™

Leukapheresis Market is projected to grow from USD 65 million in 2022 to USD 98 million by 2027, at a CAGR of 8.5% from 2022 to 2027, according to a new report by MarketsandMarkets™. While the high cost of therapeutic leukapheresis and leukopaks is expected to restrain the global Leukapheresis market during the forecast period, the increasing incidence and prevalence of leukemia, and the high demand for leukopaks in clinical research are some of the factors set to drive the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148

Browse in-depth TOC on "Leukapheresis Market"
226 - Tables
76 - Figures
294 - Pages

The Leukopaks market is projected to reach USD 784 Million by 2027 from USD 146 Million in 2022, at a CAGR of 39.8% between 2022 and 2027.

In this report, the overall Leukapheresis Market is divided into two sub-markets, the Leukapheresis Products Market and the Leukopaks Market. The Leukapheresis Products Market is classified into four segments-type, application, end user, and region, and the Leukopaks Market is classified into four segments-type, indication, end user, and region.

"In 2021, the disposables segment accounted for the larger share of the leukapheresis products market."

By type, the leukapheresis products market can be segmented into devices and disposables. The disposables segment occupied a larger share of the Leukapheresis Products market in 2021. The large share of this segment can be attributed to the recurrent use of disposables during leukapheresis procedures, the increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.

"The mobilized leukopaks segment accounted for the largest share of the leukopaks market in 2021."

By type, the leukopaks market can be segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized leukopaks segment accounted for the largest share of the Leukapheresis market in 2021. The large share of the segment can be attributed to a large number of mononuclear cells (MNCs) in these leukopaks compared to non-mobilized leukopaks, which increases their utility in research applications.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=20283148

"In 2021, North America was the region with the largest market share in the Leukapheresis market"

The Leukapheresis market is segmented into four major regions, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World.

North America accounted for the largest share of the Leukapheresis market in 2021. The strong presence of a large number of players and a large number of ongoing CAR T-cell therapy clinical trials are driving the growth of the leukapheresis market in the North American region.

Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).

Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US)

These companies adopted strategies such as product launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=20283148

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.